{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-065274","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.447217+00:00","generated_at":"2026-06-11T18:54:06.732186+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS","bullets":["Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.","Positive Phase 2 MIRA trial met primary endpoint HiSCR75 at week 12; sonelokimab showed highest clinical activity among tested therapies.","Completed randomization of 200 patients in Phase 2 ARGO PsA trial ahead of schedule; top-line 12-week data expected H1 Nov 2023.","R&D expenses $8.7M, G&A $4.5M for Q2 2023; no revenue (clinical-stage biotech).","Upcoming catalysts: MIRA 24-week data mid-Oct, ARGO 12-week data Nov, End of Phase 2 FDA meeting Dec 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-065274","json":"https://secwatch.observer/filing/0001213900-23-065274.json","markdown":"https://secwatch.observer/filing/0001213900-23-065274.md","text":"https://secwatch.observer/filing/0001213900-23-065274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/0001213900-23-065274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/ea183237-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:54:06.732186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fff1f1936bb4a64f298dfe5c8c757aea567b2bcb","claim":"MoonLake Immunotherapeutics reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Moonlake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/0001213900-23-065274-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}